<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00726609</url>
  </required_header>
  <id_info>
    <org_study_id>P04641</org_study_id>
    <nct_id>NCT00726609</nct_id>
  </id_info>
  <brief_title>Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)</brief_title>
  <official_title>Post-marketing Surveillance (PMS) Management of Invasive Mycosis With Posaconazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this postmarketing surveillance study is to collect an extensive body of data
      in a large patient population in every day life to investigate the safety and efficacy of
      NOXAFIL® (posaconazole) in the treatment of invasive fungal disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data regarding demographics, underlying disease, prior fungal infection, prior antifungal
      medication, invasive fungal infection signs &amp; symptoms, concomitant medication, posaconazole
      use, tolerability, safety and therapy outcome will be collected on abstracted electronic Case
      Report Forms.

      This surveillance study was originally limited to subjects receiving posaconazole as salvage
      antifungal therapy as indicated. A subgroup of subjects at risk for invasive fungal infection
      was included for prophylactic treatment following the enlargement of the marketing
      authorization for NOXAFIL® (posaconazole) during the course of the study. These participants
      only contributed data for the assessment of safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Adverse Drug Reactions.</measure>
    <time_frame>Before starting treatment with posaconazole, during treatment, and until 100 days after treatment.</time_frame>
    <description>The severity of an Adverse Drug Reaction is determined on the basis of the following definitions:
Mild: The abnormality, symptom or event is noticed but well tolerated.
Moderate: Symptoms impair normal activities and may require intervention.
Severe: Clinical status is significantly impaired, normal activity is no longer possible, intervention is required.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">214</enrollment>
  <condition>Mycoses</condition>
  <arm_group>
    <arm_group_label>Posaconazole (assigned by physician in normal practice)</arm_group_label>
    <description>Treatment of invasive fungal infection.
Prophylaxis of invasive fungal infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole</intervention_name>
    <description>The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.</description>
    <arm_group_label>Posaconazole (assigned by physician in normal practice)</arm_group_label>
    <other_name>SCH 56592</other_name>
    <other_name>NOXAFIL®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with invasive fungal infection refractory to first-line treatment or unable to
        tolerate it were selected at hospitals in Germany.

        Following the enlargement of the marketing authorization for posaconazole, subjects at risk
        for invasive fungal infection were also enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult subjects with:

          -  Invasive aspergillosis refractory to, or intolerant of, amphotericin B or
             itraconazole,

          -  Fusariosis refractory to, or intolerant of, amphotericin B,

          -  Chromoblastomycosis and mycetoma refractory to, or intolerant of, itraconazole,

          -  Coccidiomycosis refractory to, or intolerant of, amphotericin B, itraconazole or
             fluconazole.

          -  Subjects receiving remission-induction chemotherapy for acute myelogenous leukemia
             (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia
             and who are at high risk for developing invasive fungal infections.

          -  Hematopoietic stem-cell transplant (HSCT) recipients who are undergoing high-dose
             immunosuppressive therapy for Graft-versus-host disease and who are at high risk for
             developing invasive fungal infections.

        Exclusion Criteria:

          -  Comedication of the participant with ergotamine, dihydroergotamine, terfenadine,
             astemizole, cisapride, pimozide, halofantrine, or chinidine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2008</study_first_submitted>
  <study_first_submitted_qc>July 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2008</study_first_posted>
  <results_first_submitted>August 13, 2009</results_first_submitted>
  <results_first_submitted_qc>August 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 22, 2009</results_first_posted>
  <last_update_submitted>February 16, 2015</last_update_submitted>
  <last_update_submitted_qc>February 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Posaconazole (Assigned by Physician in Normal Practice)</title>
          <description>Treatment of invasive fungal infection.
Prophylaxis of invasive fungal infection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="116">For 26 participants in the Missing category, it is unknown if they completed the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Posaconazole (Assigned by Physician in Normal Practice)</title>
          <description>Treatment of invasive fungal infection.
Prophylaxis of invasive fungal infection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="214"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" spread="12.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Adverse Drug Reactions.</title>
        <description>The severity of an Adverse Drug Reaction is determined on the basis of the following definitions:
Mild: The abnormality, symptom or event is noticed but well tolerated.
Moderate: Symptoms impair normal activities and may require intervention.
Severe: Clinical status is significantly impaired, normal activity is no longer possible, intervention is required.</description>
        <time_frame>Before starting treatment with posaconazole, during treatment, and until 100 days after treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole (Assigned by Physician in Normal Practice)</title>
            <description>Treatment of invasive fungal infection.
Prophylaxis of invasive fungal infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Adverse Drug Reactions.</title>
          <description>The severity of an Adverse Drug Reaction is determined on the basis of the following definitions:
Mild: The abnormality, symptom or event is noticed but well tolerated.
Moderate: Symptoms impair normal activities and may require intervention.
Severe: Clinical status is significantly impaired, normal activity is no longer possible, intervention is required.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Posaconazole (Assigned by Physician in Normal Practice)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOTIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>CYSTIC LYMPHANGIOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>INJECTION SITE THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>HEPATOTOXICITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE GRAFT VERSUS HOST DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>ACUTE GRAFT VERSUS HOST DISEASE IN INTESTINE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>ACUTE GRAFT VERSUS HOST DISEASE IN LIVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>ABSCESS SWEAT GLAND</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>PSEUDOMONAL SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>TRANSFUSION REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>BLOOD CULTURE POSITIVE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>RENAL FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>FACET JOINT SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>MYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>PROSTATIC ADENOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CRITICAL ILLNESS POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>TOXIC NEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>TRANSIENT PSYCHOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PRERENAL FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>SUBCLAVIAN VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

